Sartorius Stedim Biotech S.A.

DB:56S1 Stock Report

Market Cap: €18.3b

Sartorius Stedim Biotech Valuation

Is 56S1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 56S1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 56S1 (€186.2) is trading above our estimate of fair value (€120.97)

Significantly Below Fair Value: 56S1 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 56S1?

Key metric: As 56S1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 56S1. This is calculated by dividing 56S1's market cap by their current earnings.
What is 56S1's PE Ratio?
PE Ratio114.1x
Earnings€160.60m
Market Cap€18.32b

Price to Earnings Ratio vs Peers

How does 56S1's PE Ratio compare to its peers?

The above table shows the PE ratio for 56S1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.2x
1SXP SCHOTT Pharma KGaA
24.2x15.7%€3.6b
GXI Gerresheimer
22x21.8%€2.6b
MRK Merck KGaA
22.3x11.1%€61.3b
DIVISLAB Divi's Laboratories
84.2x23.7%₹1.5t
56S1 Sartorius Stedim Biotech
114.1x32.0%€18.3b

Price-To-Earnings vs Peers: 56S1 is expensive based on its Price-To-Earnings Ratio (114.1x) compared to the peer average (38.6x).

Price to Earnings Ratio vs Industry

How does 56S1's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
56S1 114.1xIndustry Avg. 38.2xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 56S1 is expensive based on its Price-To-Earnings Ratio (114.1x) compared to the European Life Sciences industry average (38.6x).

Price to Earnings Ratio vs Fair Ratio

What is 56S1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

56S1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio114.1x
Fair PE Ratio27.6x

Price-To-Earnings vs Fair Ratio: 56S1 is expensive based on its Price-To-Earnings Ratio (114.1x) compared to the estimated Fair Price-To-Earnings Ratio (27.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 56S1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€186.20
€222.53
+19.5%
15.8%€310.00€172.00n/a15
Dec ’25€179.85
€220.67
+22.7%
18.2%€310.00€134.00n/a15
Nov ’25€183.15
€220.67
+20.5%
18.2%€310.00€134.00n/a15
Oct ’25€187.45
€213.93
+14.1%
20.5%€310.00€134.00n/a14
Sep ’25€183.10
€207.31
+13.2%
20.8%€310.00€134.00n/a13
Aug ’25€183.45
€207.31
+13.0%
20.8%€310.00€134.00n/a13
Jul ’25€150.35
€247.17
+64.4%
17.8%€360.00€180.00n/a12
Jun ’25€182.85
€248.83
+36.1%
16.8%€360.00€200.00n/a12
May ’25€209.30
€251.33
+20.1%
16.9%€360.00€200.00n/a12
Apr ’25€262.20
€261.23
-0.4%
15.8%€360.00€205.00n/a12
Mar ’25€254.90
€254.69
-0.08%
17.1%€360.00€190.00n/a14
Feb ’25€248.70
€253.12
+1.8%
18.3%€360.00€190.00n/a14
Jan ’25€239.20
€230.56
-3.6%
14.8%€310.00€175.00n/a12
Dec ’24€206.60
€224.31
+8.6%
14.5%€310.00€175.00€179.8512
Nov ’24€178.50
€252.42
+41.4%
22.5%€390.00€175.00€183.1512
Oct ’24€220.80
€308.73
+39.8%
12.3%€390.00€265.00€187.4511
Sep ’24€262.50
€306.45
+16.7%
12.5%€390.00€270.00€183.1011
Aug ’24€283.80
€303.73
+7.0%
13.5%€390.00€250.00€183.4511
Jul ’24€222.00
€334.18
+50.5%
22.7%€530.00€250.00€150.3511
Jun ’24€246.60
€363.82
+47.5%
18.5%€530.00€285.00€182.8511
May ’24€240.60
€376.70
+56.6%
17.6%€530.00€300.00€209.3010
Apr ’24€283.80
€395.27
+39.3%
10.5%€455.00€306.00€262.2011
Mar ’24€306.20
€395.91
+29.3%
10.7%€455.00€306.00€254.9011
Feb ’24€324.80
€394.73
+21.5%
10.3%€455.00€306.00€248.7011
Jan ’24€308.10
€411.20
+33.5%
12.3%€470.00€290.00€239.2010
Dec ’23€323.20
€411.20
+27.2%
12.3%€470.00€290.00€206.6010

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 15:58
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sartorius Stedim Biotech S.A. is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stéphan DubosqArkeon Finance
Charles Pitman-KingBarclays
Scott BardoBerenberg